2020 American Transplant Congress
Investigation of Il35 Expressing Regulatory B Cells in Tolerance of Kidney Transplantation
Surgery, University of Wisconsin, Madison, WI
*Purpose: The development and maintenance of peripheral tolerance is required for long term success of solid organ transplantation without immuno-suppressive drugs. Using a novel, post-transplant,…2020 American Transplant Congress
Survival after Lung Transplantation by Discharge Immunosuppressive Regimen: An Analysis of Organ Procurement and Transplantation Network Data
*Purpose: As the optimal immunosuppressive (IS) regimen after lung (LU) transplant (TX) is unknown, we conducted an analysis to compare the effect of four different…2020 American Transplant Congress
Clinical Outcomes from a Mobile Health, Pharmacist-Led Intervention: 12-Month Results of the Transafe Rx Randomized Controlled Trial
Med Univ of South Carolina, Charleston, SC
*Purpose: Medication errors and non-adherence are predominant causes of poor graft outcomes in kidney transplant (KTX) recipients. The primary aim of the TRANSAFE Rx RCT…2020 American Transplant Congress
Belatacept Suppresses the B-Cell Alloresponse in the Lower Range of Therapeutic Trough Concentrations
1Plexision, Pittsburgh, PA, 2Bristol-Myers-Squibb, Princeton, NJ
*Purpose: Background: Kidney recipients treated with the T-cell costimulation blocker, belatacept, experience a higher incidence of acute cellular rejection (ACR) and lower incidence of donor-specific…2020 American Transplant Congress
Pharmacokinetic Evaluation of a De Novo Envarsus XR® (tacrolimus Extended Release) Dosing Strategy in Kidney Transplant Recipients
*Purpose: Envarsus XR® is a once-daily tablet formulation of tacrolimus recently approved for the prophylaxis of organ rejection in de novo kidney transplant recipients (KTx).…2020 American Transplant Congress
Kidney Transplant Recipients with De Novo Donor Specific Antibody is Associated with Increased Risk of Developing BK Viremia
*Purpose: Background: De novo donor specific anti-HLA antibodies (dnDSA) has profound effect on the renal graft long-term function and survival. Studies has shown identifications of…2020 American Transplant Congress
Discontinuation Rates in Multicenter Trials – Are They Driven by Attitudes or Facts?
*Purpose: The ATHENA [NCT01843348] and Hephaistos [NCT01551212] trials were designed to compare everolimus [EVR] in combination with reduced tacrolimus [rTAC] or reduced cyclosporine A [rCyA]…2020 American Transplant Congress
Incidence and Outcomes of Secondary Cutaneous Malignancies among Renal Transplant Recipients
1Keck School of Medicine, LA, CA, 2Cedar Sinai Hospital, LA, CA
*Purpose: Solid-organ transplant recipients on immunosuppressive therapy are known to have higher morbidity and mortality from secondary malignancies; however, there are no established guidelines for…2020 American Transplant Congress
High PRA Increases Rejection but Does Not Worsen Renal Function in the First Year Post Kidney Transplant with Alemtuzumab Induction
Ochsner Medical Center, New Orleans, LA
*Purpose: Sensitization is an important immunologic risk factor considered in renal allograft allocation and influences immunosuppression. Unfortunately, there is a lack of consensus regarding the…2020 American Transplant Congress
Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain
*Purpose: Immunobiogram (IMBG) is a new IVD bioassay developed by Biohope SL with the aim to support clinicians in the personalized adjustment of immunosuppressive therapy…
- « Previous Page
- 1
- …
- 42
- 43
- 44
- 45
- 46
- …
- 138
- Next Page »